David F. Welch - 24 Feb 2022 Form 4 Insider Report for Infinera Corp

Role
Director
Signature
/s/ Michael Hopp, by Power of Attorney
Issuer symbol
N/A
Transactions as of
24 Feb 2022
Net transactions value
-$5,010,080
Form type
4
Filing time
28 Feb 2022, 17:28:15 UTC
Previous filing
07 Jan 2022
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INFN Common Stock Sale $1,357,500 -150,000 -21% $9.05 553,541 24 Feb 2022 See Footnote F1, F2
transaction INFN Common Stock Sale $1,825,000 -200,000 -36% $9.12 353,541 25 Feb 2022 See Footnote F2, F3
transaction INFN Common Stock Sale $1,827,580 -200,000 -57% $9.14 153,541 28 Feb 2022 See Footnote F2, F4
holding INFN Common Stock 2,500 24 Feb 2022 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price represents the weighted average sale price of the shares sold in multiple transactions at prices ranging from $9.00 to $9.10 per share. Upon request by the staff of the Securities and Exchange Commission, Infinera Corporation (the "Company") or a security holder of the Company, Dr. Welch will provide full information regarding the number of shares sold at each separate price.
F2 These shares are held directly by The Welch Family Trust U/A DTD 4/3/1996 ("The Welch Family Trust"), for which Dr. Welch is a trustee.
F3 This price represents the weighted average sale price of the shares sold in multiple transactions at prices ranging from $9.10 to $9.15 per share. Upon request by the staff of the Securities and Exchange Commission, the Company or a security holder of the Company, Dr. Welch will provide full information regarding the number of shares sold at each separate price.
F4 This price represents the weighted average sale price of the shares sold in multiple transactions at prices ranging from $9.10 to $9.20 per share. Upon request by the staff of the Securities and Exchange Commission, the Company or a security holder of the Company, Dr. Welch will provide full information regarding the number of shares sold at each separate price.
F5 These shares are held directly by Dr. Welch as a trustee for his children. Dr. Welch disclaims beneficial ownership of the shares held in trust for his children, and this report shall not be deemed an admission that Dr. Welch is the beneficial owner of the shares held in trust for his children for purposes of Section 16 or for any other purpose.